Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications

References

• Mayer L. D., Tai L. C.L., Ko D. S.C., Masin D., Ginsberg R. S., Cullis P. R., Bally M. B. Influence of Vesicle Size, Lipid Composition and Drug-to-Lipid Ratio on the Biological Activity of Liposomal Doxorubicin. Cancer Res. 1989; 49: 5922–5930
   PubMed Web of Science ®Google Scholar
• Hwang K. J. Liposome pharmacokinetics. Liposomes: from Biophysics to Therapeutics, M. J. Ostro. Marcel Dekker, New York 1987; 109–156
   Google Scholar
• Allen T. M. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends in Pharm. ScL 1994; 15: 215–220
   PubMed Web of Science ®Google Scholar
• Woodle M. C., Lasic D. D. Sterically stabilized liposomes. Biochim. Biophys. Acta 1992; 1113: 171–199
   PubMed Web of Science ®Google Scholar
• Ahmad I., Longenecker M., Samuel J., Allen T. M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 1993; 53: 1484–1488
   PubMed Web of Science ®Google Scholar
• Kirpotin D., Park J. W., Hong K., Zalipsky S., Li W. L., Carter P., Benz C. C., Paphadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36: 66–75
   PubMed Web of Science ®Google Scholar
• Yuan F., Dellian M., Fukumura D., Leunig M., Berk D. A., Torchilin V. P., Jain RK. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995; 55: 3752–3756
   PubMed Web of Science ®Google Scholar
• Wu N. Z., Rudoll T. L., Needham D., Whorton A. R., Dewhirst M. W. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 1993; 53: 3765–3770
   PubMed Web of Science ®Google Scholar
• Webb M. S., Harasym T. O., Masin D., Bally M. B., Mayer L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer 1995; 72: 896–904
   PubMed Web of Science ®Google Scholar
• Parr M. J., Masin D., Cullis P. R., Bally M. B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis Lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Therapeut. 1997; 280: 1319–1324
   PubMed Web of Science ®Google Scholar
• Swenson C. E., Freitag J., Janoff A. S. The Liposome Company: Lipid-based pharmaceuticals in clinical development. Medical Applications of Liposomes, D. Lasic, D. Papahadjopoulos. Elsevier, New York, NY 1998; 689–702
   Google Scholar
• Martin F. Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin): Sequus Pharmaceuticals, Inc. Medical Applications of Liposomes, D. Lasic, D. Papahadjopoulos. Elsevier, New York, NY 1998; 635–688
   Google Scholar
• Colbern G. T., Dykes D. J., Engbers C., Musterer R., Hiller A., Pegg E., Saville R., Weng S., Luzzio M., Uster P., Amantea M., Working P. K. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts. Clin. Cancer Res. 1998; 4: 3077–3082
   PubMed Web of Science ®Google Scholar
• Adlakha-Hutcheon G., Bally M. B., Shew C. R., Madden T. D. Controlled Destabi-iization of a Liposomal Drug Delivery System Enhances Mitoxantrone Antitumor Acitivity. Nature Biotech. 1999; 17: 775–779
   PubMed Web of Science ®Google Scholar
• Newman M. S., Colbern G. T., Working P. K., Engbers C., Amantea M. A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cis-platin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 1999; 43: 1–7
   PubMed Web of Science ®Google Scholar
• Sharma A., Straubinger R. M., Ojima I., Bernacki R. J. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. of Pharm. Sci. 1995; 84: 1400–404
   PubMed Web of Science ®Google Scholar
• Park J. W., Hong K., Kirpotin D. B., Meyer O., Papahadjopoulos D., Benz C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett. 1997; 118: 153–160
   PubMed Web of Science ®Google Scholar
• Lopes de Menezes Pilarski L. M., Allen T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 1998; 58: 3320–3330
   PubMed Web of Science ®Google Scholar
• Herman E. H., Rahman A., Ferrans V. J., Vicks J. A., Schein P. S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983; 43: 5427–5432
   PubMed Web of Science ®Google Scholar
• Van Hossel Q. G.C.M., Steerenberg P. A., Crommelin D. J.A., van Dijk A., van Oost W., Klein S., Douze J. M.C., de Wildt D. J., Hillen F. C. Reduced Cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl Rat. Cancer Res. 1984; 44: 3698–3705
   PubMed Web of Science ®Google Scholar
• Rahman A., White G., Moore N., Schein P. S. Pharmacological, toxicological and therapeutic evaluation in mice of doxorubicin entrapped in liposomes. Cancer Res. 1985; 45: 796–803
   PubMed Web of Science ®Google Scholar
• Hong R. L., Huang C. J., Tseng Y. L., Pang V. F., Chen S. T., Liu J. J., Chang F. H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?. Clin. Cancer Res. 1999; 5: 3645–3652
   PubMed Web of Science ®Google Scholar
• Lum B., Gosland M. MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprotein inhibitors. Hematol. Oncol. Clin. North Am. 1995; 9: 319
   PubMed Web of Science ®Google Scholar
• Colombo T., Paz O. G., D'lncalci M. Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukemia. Br. J. Cancer 1996; 73: 866–873
   PubMed Web of Science ®Google Scholar
• Krishna R., Mayer L. D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors. Cancer Res. 1997; 57: 5246
   PubMed Web of Science ®Google Scholar
• Krishna R., St Louis M., Mayer L. D. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administring Valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int. J. Cancer 2000; 85: 131–141
   PubMed Web of Science ®Google Scholar
• Krishna R., McIntosh N., Riggs K. W., Mayer L. D. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of Valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin. Cancer Res. 1999; 5: 2939–2947
   PubMed Web of Science ®Google Scholar
• Mayer L. D., Bally M. B., Loughrey H., Masin D., Cullis P. R. Liposomal Vincristine Preparations Which Exhibit Decreased Toxicity and Increased Anti-tumour Activity Against Murine L1210 and P388 Tumours. Cancer Research 1990; 50: 575–579
   PubMed Web of Science ®Google Scholar
• Mayer L. D., Masin D., Nayar R., Boman N. L., Bally M. B. Pharmacology of Liposomal Vincristine in Mice Bearing L1210 Ascitic and B16/BL6 Solid Tumors. British J. Cancer 1995; 71: 482–488
   PubMed Web of Science ®Google Scholar
• Boman N. L., Mayer L. D., Cullis P. R. Optimization of Vincristine Retention in Liposomes In Vitro and In Vivo. Biochim. Biophys. Acta 1993; 1152: 253–260
   PubMed Web of Science ®Google Scholar
• Bowman N. L., Masin D., Mayer L. D., Cullis P. R., Bally M. B. Liposomal Vincristine Which Exhibits Increased Drug Retention and Increased Circulation Longevity Cures Mice Bearing P388 Tumors. Cancer Res. 1994; 54: 2830–2833
   PubMed Web of Science ®Google Scholar